BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cliramitug readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cliramitug\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06183931-11166@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20271206
DTEND;VALUE=DATE:20271207
SUMMARY:Cliramitug: Phase 3 readout est. (NCT06183931)
DESCRIPTION:Cliramitug\, phase 3\, Transthyretin Amyloidosis with Cardiomyo
 pathy.\nStudy: Study of ALXN2220 Versus Placebo in Adults With ATTR-CM\nEs
 timated primary completion: 6 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/cliramitug#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06183931
URL:https://assetmemo.bio/drug/cliramitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07608354-11166@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20290206
DTEND;VALUE=DATE:20290207
SUMMARY:Cliramitug: Phase 2 readout est. (NCT07608354)
DESCRIPTION:Cliramitug\, phase 2\, Transthyretin Amyloidosis with Cardiomyo
 pathy.\nStudy: A Study to Evaluate the Efficacy and Safety of Concomitant 
 Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for 
 Adults Participants With ATTR-CM\nEstimated primary completion: 6 February
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/cliramitug#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0760835
 4
URL:https://assetmemo.bio/drug/cliramitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07789483-11166@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20300711
DTEND;VALUE=DATE:20300712
SUMMARY:Cliramitug: Phase 3 readout est. (NCT07789483)
DESCRIPTION:Cliramitug\, phase 3\, Transthyretin Amyloidosis with Cardiomyo
 pathy.\nStudy: An Open-Label Study to Evaluate the Long-Term Safety and Ef
 ficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy\nEs
 timated primary completion: 11 July 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/cliramitug#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07789483
URL:https://assetmemo.bio/drug/cliramitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
